CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Biomea Fusion, Inc. - BMEA CFD

    12.98
    1.02%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.24
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026207 %
    Charges from full value of position ($-4.98)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026207%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003985 %
    Charges from full value of position ($0.76)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003985%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Biomea Fusion Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 12.7
    Open* 13.16
    1-Year Change* 87.2%
    Day's Range* 12.61 - 13.16
    52 wk Range 6.04-43.69
    Average Volume (10 days) 457.51K
    Average Volume (3 months) 9.64M
    Market Cap 354.92M
    P/E Ratio -100.00K
    Shares Outstanding 35.71M
    Revenue N/A
    EPS -3.34
    Dividend (Yield %) N/A
    Beta -100.00K
    Next Earnings Date N/A

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Nov 29, 2023 12.70 -1.81 -12.47% 14.51 15.08 12.69
    Nov 28, 2023 9.89 0.01 0.10% 9.88 9.98 9.46
    Nov 27, 2023 9.91 -0.14 -1.39% 10.05 10.37 9.71
    Nov 24, 2023 10.21 0.26 2.61% 9.95 10.42 9.91
    Nov 22, 2023 9.97 0.10 1.01% 9.87 10.26 9.71
    Nov 21, 2023 9.88 -0.10 -1.00% 9.98 10.14 9.60
    Nov 20, 2023 10.26 0.03 0.29% 10.23 10.95 10.11
    Nov 17, 2023 10.32 1.29 14.29% 9.03 10.81 8.96
    Nov 16, 2023 9.25 -0.51 -5.23% 9.76 9.76 8.88
    Nov 15, 2023 9.25 0.48 5.47% 8.77 10.20 8.77
    Nov 14, 2023 8.84 0.37 4.37% 8.47 9.02 8.41
    Nov 13, 2023 8.31 -0.02 -0.24% 8.33 8.34 8.06
    Nov 10, 2023 8.43 -0.08 -0.94% 8.51 8.59 8.09
    Nov 9, 2023 8.55 -0.37 -4.15% 8.92 9.18 8.54
    Nov 8, 2023 9.01 -0.27 -2.91% 9.28 9.28 8.72
    Nov 7, 2023 9.26 0.25 2.77% 9.01 9.71 9.00
    Nov 6, 2023 9.23 -0.82 -8.16% 10.05 10.05 9.06
    Nov 3, 2023 10.02 0.15 1.52% 9.87 10.44 9.86
    Nov 2, 2023 10.00 -0.41 -3.94% 10.41 11.14 9.76
    Nov 1, 2023 10.39 0.51 5.16% 9.88 10.39 9.74

    Biomea Fusion, Inc. Events

    Time (UTC) Country Event
    No events scheduled
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019
    Total revenue 0 0 0 0
    Total Operating Expense 83.634 41.667 5.327 1.195
    Selling/General/Admin. Expenses, Total 20.921 13.671 1.656 0.103
    Research & Development 62.713 27.996 3.671 1.092
    Operating Income -83.634 -41.667 -5.327 -1.195
    Interest Income (Expense), Net Non-Operating 1.806 0.1 0.003 -0.003
    Net Income Before Taxes -81.828 -41.567 -5.324 -1.198
    Net Income After Taxes -81.828 -41.567 -5.324 -1.198
    Net Income Before Extra. Items -81.828 -41.567 -5.324 -1.198
    Net Income -81.828 -41.567 -5.324 -1.198
    Income Available to Common Excl. Extra. Items -81.828 -41.567 -5.324 -1.198
    Income Available to Common Incl. Extra. Items -81.828 -41.567 -5.324 -1.198
    Diluted Net Income -81.828 -41.567 -5.324 -1.198
    Diluted Weighted Average Shares 29.2718 23.8585 28.7679 28.7679
    Diluted EPS Excluding Extraordinary Items -2.79546 -1.74223 -0.18507 -0.04164
    Dividends per Share - Common Stock Primary Issue 0 0
    Diluted Normalized EPS -2.79546 -1.74223 -0.18507 -0.04164
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 0 0 0 0 0
    Total Operating Expense 27.657 30.031 26.276 23.484 17.474
    Selling/General/Admin. Expenses, Total 5.719 5.636 5.737 5.242 4.892
    Research & Development 21.938 24.395 20.539 18.242 12.582
    Operating Income -27.657 -30.031 -26.276 -23.484 -17.474
    Interest Income (Expense), Net Non-Operating 2.766 0.98 0.962 0.594 0.216
    Net Income Before Taxes -24.891 -29.051 -25.314 -22.89 -17.258
    Net Income After Taxes -24.891 -29.051 -25.314 -22.89 -17.258
    Net Income Before Extra. Items -24.891 -29.051 -25.314 -22.89 -17.258
    Net Income -24.891 -29.051 -25.314 -22.89 -17.258
    Income Available to Common Excl. Extra. Items -24.891 -29.051 -25.314 -22.89 -17.258
    Income Available to Common Incl. Extra. Items -24.891 -29.051 -25.314 -22.89 -17.258
    Diluted Net Income -24.891 -29.051 -25.314 -22.89 -17.258
    Diluted Weighted Average Shares 35.3483 29.5865 29.4435 29.319 29.1964
    Diluted EPS Excluding Extraordinary Items -0.70416 -0.9819 -0.85975 -0.78072 -0.5911
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.70416 -0.9819 -0.85975 -0.78072 -0.5911
    • Annual
    • Quarterly
    2022 2021 2020 2019
    Total Current Assets 117.819 176.561 62.223 0.265
    Cash and Short Term Investments 113.049 173.516 61.695 0.239
    Cash & Equivalents 111.899 145.736 61.695 0.239
    Prepaid Expenses 4.77 3.045 0.492 0.015
    Other Current Assets, Total 0.036 0.011
    Total Assets 129.307 185.705 62.526 0.265
    Property/Plant/Equipment, Total - Net 7.992 5.687 0.291 0
    Property/Plant/Equipment, Total - Gross 8.908 5.944 0.299 0
    Accumulated Depreciation, Total -0.916 -0.257 -0.008 0
    Other Long Term Assets, Total 3.496 1.581 0.012 0
    Total Current Liabilities 19.101 4.637 1.619 0.286
    Accounts Payable 6.826 1.329 0.727 0.271
    Accrued Expenses 11.639 2.828 0.856 0.015
    Notes Payable/Short Term Debt 0 0 0.036 0
    Total Liabilities 20.768 6.922 1.619 0.286
    Total Long Term Debt 0 0 0 0
    Total Equity 108.539 178.783 60.907 -0.021
    Preferred Stock - Non Redeemable, Net 0 55.738 0
    Common Stock 0.003 0.003 0.001 0.001
    Additional Paid-In Capital 240.107 228.532 13.343 2.829
    Retained Earnings (Accumulated Deficit) -131.57 -49.742 -8.175 -2.851
    Total Liabilities & Shareholders’ Equity 129.307 185.705 62.526 0.265
    Total Common Shares Outstanding 29.5616 29.1156 28.7679 28.7679
    Short Term Investments 1.15 27.78
    Long Term Investments 0 1.876
    Other Current Liabilities, Total 0.636 0.48
    Other Liabilities, Total 1.667 2.285
    Other Equity, Total -0.001 -0.01
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 202.504 225.936 88.931 117.819 138.861
    Cash and Short Term Investments 199.09 222.908 86.3 113.049 133.458
    Cash & Equivalents 199.09 222.908 86.3 111.899 132.311
    Short Term Investments 0 0 0 1.15 1.147
    Total Receivables, Net
    Accounts Receivable - Trade, Net
    Prepaid Expenses 3.414 3.028 2.631 4.77 5.403
    Other Current Assets, Total
    Total Assets 225.087 248.674 112.638 129.307 145.05
    Property/Plant/Equipment, Total - Net 17.385 18.481 19.467 7.992 5.345
    Property/Plant/Equipment, Total - Gross 19.396 20.073 20.676 8.908 6.078
    Accumulated Depreciation, Total -2.011 -1.592 -1.209 -0.916 -0.733
    Long Term Investments 0 0.01
    Other Long Term Assets, Total 5.198 4.257 4.24 3.496 0.834
    Total Current Liabilities 16.21 14.357 18.774 19.101 12.589
    Accounts Payable 3.194 4.154 5.329 6.826 1.592
    Accrued Expenses 12.852 9.804 13.02 11.639 10.569
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 0.164 0.399 0.425 0.636 0.428
    Total Liabilities 25.475 24.369 29.509 20.768 14.415
    Total Long Term Debt 0 0 0 0 0
    Total Equity 199.612 224.305 83.129 108.539 130.635
    Preferred Stock - Non Redeemable, Net 0
    Common Stock 0.004 0.004 0.003 0.003 0.003
    Additional Paid-In Capital 413.549 409.813 243.747 240.107 236.901
    Retained Earnings (Accumulated Deficit) -213.941 -185.512 -160.621 -131.57 -106.256
    Other Equity, Total 0 0 0 -0.001 -0.013
    Total Liabilities & Shareholders’ Equity 225.087 248.674 112.638 129.307 145.05
    Total Common Shares Outstanding 35.6988 35.6303 29.6511 29.5616 29.3888
    Other Liabilities, Total 9.265 10.012 10.735 1.667 1.826
    • Annual
    • Quarterly
    2022 2021 2020 2019
    Net income/Starting Line -81.828 -41.567 -5.324 -1.198
    Cash From Operating Activities -62.417 -35.438 -4.459 -1.279
    Cash From Operating Activities 0.691 0.249 0.008 0
    Non-Cash Items 11.051 7.454 0.446 0
    Changes in Working Capital 7.669 -1.574 0.411 -0.081
    Cash From Investing Activities 27.341 -33.355 -0.051 0
    Capital Expenditures -1.03 -3.171 -0.051 0
    Cash From Financing Activities 1.239 153.185 65.966 1.44
    Issuance (Retirement) of Stock, Net 1.239 153.221 65.93 1.44
    Issuance (Retirement) of Debt, Net 0 -0.036 0.036 0
    Net Change in Cash -33.837 84.392 61.456 0.161
    Other Investing Cash Flow Items, Total 28.371 -30.184
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -29.051 -81.828 -56.514 -33.624 -16.366
    Cash From Operating Activities -24.044 -62.417 -42.216 -25.421 -9.994
    Cash From Operating Activities 0.293 0.691 0.51 0.336 0.166
    Non-Cash Items 3.846 11.051 8.182 5.297 2.57
    Changes in Working Capital 0.868 7.669 5.606 2.57 3.636
    Cash From Investing Activities -1.756 27.341 28.042 27.817 20.442
    Capital Expenditures -2.906 -1.03 -0.318 -0.368 -0.095
    Other Investing Cash Flow Items, Total 1.15 28.371 28.36 28.185 20.537
    Cash From Financing Activities 0.201 1.239 0.749 0.349 0.031
    Issuance (Retirement) of Stock, Net 0.201 1.239 0.749 0.349 0.031
    Issuance (Retirement) of Debt, Net 0 0 0 0
    Net Change in Cash -25.599 -33.837 -13.425 2.745 10.479
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    Fidelity Management & Research Company LLC Investment Advisor 14.903 5310165 315267 2023-06-30 LOW
    Cormorant Asset Management, LP Hedge Fund 10.0217 3570872 0 2023-06-30 LOW
    A2A Pharmaceuticals Inc Corporation 9.8227 3500000 -50000 2023-06-01 LOW
    Butler (Thomas Andrew) Individual Investor 8.3471 2974197 480790 2023-04-03
    Janus Henderson Investors Investment Advisor/Hedge Fund 8.0004 2850670 -265387 2023-06-30 LOW
    Laurion Capital Management LP Hedge Fund 6.2969 2243687 1689287 2023-06-30 HIGH
    Baker Bros. Advisors LP Hedge Fund 5.9188 2108949 0 2023-06-30 LOW
    Erdtmann (Rainer M) Individual Investor 5.7927 2064030 -480790 2023-04-03
    State Street Global Advisors (US) Investment Advisor/Hedge Fund 4.4005 1567950 1511635 2023-06-30 LOW
    BlackRock Institutional Trust Company, N.A. Investment Advisor 4.2841 1526500 1069591 2023-06-30 LOW
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 3.6847 1312909 223561 2023-06-30 LOW
    Driehaus Capital Management, LLC Investment Advisor/Hedge Fund 3.3074 1178471 328979 2023-06-30 MED
    Rock Springs Capital Management LP Hedge Fund 2.3488 836898 -460315 2023-06-30 LOW
    Aisling Capital Management LP Investment Advisor/Hedge Fund 2.2417 798757 0 2023-06-30 LOW
    Perceptive Advisors LLC Private Equity 2.0107 716441 391441 2023-06-30 MED
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.2076 430296 218011 2023-06-30 LOW
    BlackRock Financial Management, Inc. Investment Advisor/Hedge Fund 0.9714 346113 -135609 2023-06-30 LOW
    Woodline Partners LP Hedge Fund 0.9589 341673 0 2023-06-30 HIGH
    Millennium Management LLC Hedge Fund 0.9322 332174 45143 2023-06-30 HIGH
    Ikarian Capital LLC Hedge Fund 0.7742 275875 64900 2023-06-30 HIGH

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Biomea Fusion, Inc. Company profile

    About Biomea Fusion Inc

    Biomea Fusion, Inc. is a preclinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The Company has built FUSION System discovery platform to advance a pipeline of irreversible small molecule product candidates. The Company's lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The Company is developing BMF-219 for the treatment of liquid and solid tumors that are dependent on menin, including leukemias containing the mixed lineage leukemia (MLL) fusion protein. The Company is also advancing other preclinical irreversible programs for the treatment of select cancers.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, Biomea Fusion Inc revenues was not reported. Net loss increased from $5.3M to $41.6M. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.19 to -$1.74.

    Industry: Biotechnology & Medical Research (NEC)

    900 Middlefield Road, 4th Floor
    REDWOOD CITY
    CALIFORNIA 94063
    US

    Income Statement

    • Annual
    • Quarterly

    News

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023
    GBP

    UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?

    UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.

    10:48, 21 November 2023

    Gold Rises as Traders price-in Fed Rate Cuts

    Gold prices have declined despite a drop in Treasury yields and a weaker US Dollar. We look at the key drivers and technical levels for the gold price.

    13:17, 20 November 2023

    People also watch

    US100

    16,012.90 Price
    +0.110% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 22:00 (UTC)
    Spread 1.8

    XRP/USD

    0.61 Price
    -0.880% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 22:00 (UTC)
    Spread 0.01168

    BTC/USD

    37,806.50 Price
    -0.020% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 22:00 (UTC)
    Spread 106.00

    Gold

    2,038.24 Price
    -0.310% 1D Chg, %
    Long position overnight fee -0.0196%
    Short position overnight fee 0.0114%
    Overnight fee time 22:00 (UTC)
    Spread 0.50

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading